wbur In this 2016 photo, a Chinese doctor Peng Limei looks at a CT scan of a lung cancer patient. (Andy Wong/AP)
This story is part of our "This Moment In Cancer" series. Sign up here to get series updates in your inbox.
A dear friend died of lung cancer this week.
She didnt smoke and she had no other risk factors. A retired nurse and avid cook, she ate an exemplary diet, maintained a lithe figure, and got an impressive amount of exercise climbing mountains and clearing trails.
Her death has left her many friends wondering why her? Her example undercuts the notion that any of us can ultimately do much to avoid an ugly death from cancer.
Dr. Bert Vogelstein of Johns Hopkins Medical Institutions says my late friend exemplifies the 50 percent or so of cancers he calls unpreventable.
"People want a reason why these cancers happen," Vogelstein says. "Well, heres the reason: Cells make mistakes. Thats just bad luck."
Those mistakes are like typos in a giant manuscript. Each time a cell divides, it mis-copies several molecules in the long chain of DNA that makes up our genes. Most of the time these biochemical mistakes are harmless. But sometimes they occur in genes that keep cancer in check. Once some of these mutations accumulate, the cell breaks free of normal constraints on its growth --that is, it becomes malignant.
"People want a reason why these cancers happen. Well, heres the reason: Cells make mistakes. Thats just bad luck."
Two-thirds of the mutations that give rise to cancer are these random copying errors, according to Vogelstein, biostatistician Cristian Tomasetti and their colleagues at Johns Hopkins University. Another 29 percent of cancer-causing DNA damage, they say, comes from environmental and behavioral factors such as cigarette smoking and obesity. The remaining 5percent are hereditary defects.
Vogelstein is a leading light in cancer research. He pioneered the concept that there are genes that suppress cancer and identified mutations in those genes that underlie many cancers.
The Hopkins researchers have been saying for two years that most cancer-causing mutations are these inescapable random errors at the heart of our most fundamental cellular workings. But their 2015 paper was heavily criticized, partly because it considered only U.S. cancer cases --other nations may have different or more environmental triggers. Also, the earlier report left out breast and prostate cancers, two of the most common types, so critics said it wasnt valid to generalize the findings to all cancers.
Their new paper, just published in Science, includes breast and prostate cancer in the 17 cancer types they analyzed. And it incorporates evidence on cancer incidence from 69 countries that account for two-thirds of the worlds population.
"This is the very first time that someone has ever looked at the proportion of mutations within each cancer type and assigned them to these three factors," Tomasetti said during a press briefing, referring to environment, heredity and random copying errors. "I consider this a completely new result compared to our previous one and a really fundamental one."
Their argument relies on a mathematical model that estimates the number of stem cells in each tissue type (the cells that must replicate to renew the tissue) and the number of times these cells divide over a lifetime. The rate of random mutations is fairly constant in different organs, they say, but different tissues turn over at different rates.
For instance, cells that make up the lining of the large intestine renew themselves every four days. That gives them more opportunity to accumulate mutations in the genes that drive cancer than cells in, say, the bone or brain. So it makes sense that colorectal cancer is the fourth most common major cancer, after lung, breast and prostate cancers.
What it doesn't mean
The finding that two-thirds of cancer-causing mutations are due to random mistakes does not mean that two-thirds of all cancers are due to bad luck. Thats because many cancers arise from a mix of factors.
Since it takes several mutational hits to kick-start a cancer, one or more of these might arise from internal random copying errors while others might come from external environmental sources, such as tobacco smoke. An individual born with a mutation that predisposes her to cancer might not get the disease unless or until random mutations in cancer-driving genes accumulate.
Breast cancer is an example of mixed causes. Most of the underlying mutations are due to random mutations, Vogelstein says. Some are due to an environmental factor such as obesity, age of first menstruation or whether a woman breast-fed. And about 10 percent stem from a strong hereditary predisposition, such as a BRCA gene.
Vogelstein says my late friend appears to represent a "pure" case of random bad luck, since smoking and behavioral risk factors were apparently not in play and lung cancer is not known to have a significant hereditary component.
The Hopkins teams findings, they say, are consistent with prior estimates that about 40 percent of all cancers are preventable, 5to 10 percent are due to inherited cancer genes, and around half are not preventable --since theres no way to avoid random DNA copying errors.
But what about environment?
But the work has been controversial up to now, and may remain contentious. It disturbs those who believe that changes in environment and behavior deserve top priority in the war against cancer.
Concluding that bad luck is the major cause of cancer would be misleading and may detract from efforts to identify the causes of the disease and effectively prevent it, Dr. Christopher Wild, director of the World Health Organizations International Agency for Cancer Research, complained after the first Vogelstein-Tomasetti paper came out.
Anne McTiernan of the Fred Hutchinson Cancer Research Center in Seattle remains unconvinced. "They say randomness is a major cause of cancer, and they said it last time," she told The Washington Post. "But the data doesnt convince me."
One group from Stony Brook University in New York did an analysis of the 2015 paper and concluded that extrinsic factors, such as environmental toxins, account for 70 to 90 percent of cancers while intrinsic ones the random copying errors when cells divide are to blame for only 10 to 30 percent.
The leader of the Stony Brook team says hes not convinced by the new report.
Vogelstein is philosophical about his critics. Its never easy to overturn dogma, he said in an interview. Like every new concept or idea that goes dramatically against the current paradigm, it will take awhile. It will take other people doing measurements we havent performed yet or even thought of. And hopefully people will accept it.
Less self-blame?
The implications for the way we think about cancer, and the strategies to fight it, are profound.
Most immediately, it might lessen the self-blame many cancer victims and their families feel --the sense theres something they did, or didnt do, that led to their diagnosis.
We hope this research offers comfort to the literally millions of patients who have developed cancer but who have led near-perfect lifestyles --who havent smoked, who have avoided the sun without sunscreen, who eat perfectly healthy diets, who exercise regularly, whove done everything that we know can be done to prevent cancer but they still get it, Vogelstein says.
Self-blame is particularly poignant for parents of children who get cancer. The Hopkins group believes that childhood cancers are entirely due to random mutations --except for the small percentage related to inherited gene defects.
When such parents read online that cancer is caused by environment or heredity, they often conclude theyre somehow to blame. "That causes a tremendous amount of guilt," says Vogelstein, a practicing pediatrician in his early career.
But the larger implication concerns the best strategy for fighting cancer.
Not preventing but nipping in the bud
Its not that classic prevention efforts, especially smoking cessation and healthier diets, dont deserve our continuing attention. But if around half of all cancers are due to random mutations --the price of biological mechanisms necessary for life --then theres no way to prevent those. That means we need to rely on early detection and treatment to maximize cures and minimize deaths.
We believe the first step in developing these strategies is simply recognizing these enemies exist, there are a lot of them, and theyre already here, inside us, Vogelstein says.
Right now, he says, funding for early detection and treatment is minuscule compared to that devoted to curing advanced, late-stage cancers.
One of the hottest areas of cancer research focuses on spotting the earliest signs of cancer, using such things as liquid biopsies to screen bodily fluids for evidence of cancer-causing mutations or telltale proteins produced by errant genes.
Vogelstein is prominent in this effort and has a personal stake such research. Hes the co-founder of two companies, PapGene and Personal Genome Diagnostics, that are trying to develop such high-tech diagnostics.
But early detection and treatment of cancer is fraught with pitfalls, as controversies over the risk-benefit ratio of mammography to detect early breast cancer and PSA testing for prostate cancer amply show. In large part thats because such tests often find cancers that dont need to be treated --that is, theyd never cause trouble if they werent treated. Doctors call this over-diagnosis.
There is certainly a problem with potential over-diagnosis, Vogelstein acknowledges. But that doesnt mean we should abandon the effort, especially now that were cognizant that many cancers arent preventable.
If Vogelstein and Tomasetti are right, they say, theres really no choice but to focus much more effort on nipping cancers in the bud. That's a long-term project.
Right now, for instance, many cancers are out of the gate and down the road before they're discovered. My friend's lung cancer, like so many with this fearful diagnosis, was too far advanced by the time it was found to even be slowed down by the most aggressive treatment.
So after living the healthiest life you can imagine, she spent her last days coping valiantly with the debilitating effects of the best cancer therapy her doctors could offer. It wasn't enough.
Richard Knox Senior Correspondent, CommonHealth Richard Knox is a senior correspondent for WBUR's CommonHealth.
More
Excerpt from:
A Friend Dies As Scientists Ponder: Just How Preventable Are Most Cancers? - WBUR
- Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030 - ABP Live - November 26th, 2023
- What Is Amyloidosis? All About The Rare Disease That Pervez Musharraf Suffered From - ABP Live - February 8th, 2023
- Autophagic death of neural stem cells mediates chronic stress-induced ... - November 7th, 2022
- Programmed cell death - Wikipedia - November 7th, 2022
- Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions - September 4th, 2022
- Canadian Blood Services Stem Cells for Life - September 4th, 2022
- Devastation over death of schoolgirl, 11, who hoped she was beating cancer - Leicestershire Live - September 4th, 2022
- From optimized stem cell transplants to CAR T cell therapy: Advancing options for cancer, HIV and more - City of Hope - September 4th, 2022
- Scientists unlock the key to immortality in jellyfish - Syfy - September 4th, 2022
- Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients... - September 4th, 2022
- Menin Inhibitors Have Potential to Become the Next Class of Targeted Therapy in AML - Targeted Oncology - September 4th, 2022
- Wanted murder suspect John Belfield believed to still be in the UK as two more arrested over death of Thomas Campbell - The Manc - September 4th, 2022
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal... - July 8th, 2022
- Can minds persist when they are cut off from the world? - Livescience.com - July 8th, 2022
- Black Adolescent Young Adults With AML Have Worse Outcomes Vs White Population - Cancer Network - July 8th, 2022
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in... - July 8th, 2022
- How abortion ruling could affect IVF and embryonic research - The Almanac Online - July 8th, 2022
- This Morning viewers 'in tears' after boy meets donor who saved his life - Devon Live - July 8th, 2022
- Alpena detective: 'Good people out there' | News, Sports, Jobs - Alpena News - July 8th, 2022
- 'I miss my best friend': Five-year-old runs 10k to honour girl who died from rare brain tumour - Teesside Live - July 8th, 2022
- Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by... - July 8th, 2022
- Novartis AG, AstraZeneca Plc, and Pfizer Inc Among Leading Companies in the Thyroid Cancer Pipeline Products Market | Globaldata Plc - Yahoo Finance - July 8th, 2022
- A New Strategy Could Turn the Tide in Stem Cell GVHD - Medical Device and Diagnostics Industry - January 17th, 2022
- Vertex type 1 diabetes vs stem cell therapy - The Boar - January 17th, 2022
- Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT - AJMC.com Managed Markets Network - January 17th, 2022
- Nowakowski Considers CD19 Therapy in Transplant-Ineligible DLBCL - Targeted Oncology - January 17th, 2022
- Psaki demolishes Doocy with stats as he tries to claim covid now an illness of the vaccinated - newsconcerns - January 17th, 2022
- Doctors and Researchers Probe How COVID-19 Attacks the Heart - The Scientist - January 17th, 2022
- Who does donated blood that's direly needed help? - WTOP - January 17th, 2022
- Places Where Omicron is Most Contagious Eat This Not That - Eat This, Not That - January 17th, 2022
- UHN and U of T receive $24-million federal grant for transplant research - News@UofT - January 17th, 2022
- Glycyrrhizic acid ameliorates submandibular gland oxidative stress, autophagy and vascular dysfunction in rat model of type 1 diabetes | Scientific... - January 17th, 2022
- Stem cells in cancer therapy: opportunities and challenges - January 1st, 2022
- Life After Brain Death: Is the Body Still 'Alive'? | Live ... - January 1st, 2022
- Autologous Adult Stem Cells in the Treatment of Stroke | SCCAA - Dove Medical Press - January 1st, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 1st, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 1st, 2022
- Upregulated expression of actin-like 6A is a risk factor | CMAR - Dove Medical Press - January 1st, 2022
- COVID-19 Takes a Toll on People with Blood Cancers and Disorders - Cancer Health Treatment News - January 1st, 2022
- Mental health disorders and heart diseases - Rising Kashmir - January 1st, 2022
- Research breakthrough could mean better treatment for patients with most deadly form of brain tumor - EurekAlert - October 26th, 2021
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable... - October 26th, 2021
- European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 - Galveston County Daily News - October 26th, 2021
- Everything You Need To Know About COVID Booster Shots - Colorado Times Recorder - October 26th, 2021
- Stem cells and their role in lung transplant rejection - Michigan Medicine - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Will humans ever be immortal? - Livescience.com - October 5th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Why Bezos, Musk, Page and other billionaires want to live forever - New York Post - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - ABC 12 News - October 5th, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 5th, 2021
- Skeletons' broken clavicles tell a centuries-old tale of humans and horses - Massive Science - October 5th, 2021
- Environmental Factor - August 2021: Extramural Papers of the Month - Environmental Factor Newsletter - August 4th, 2021
- Role of traumatic brain injury in the development of glioma | JIR - Dove Medical Press - August 4th, 2021
- Targeted Therapeutics Market: Increase in Incidence of Cancer to Drive Global Market - BioSpace - August 4th, 2021
- Accumulation of Regulatory T Cells in Triple Negative Breast Cancer Ca | CMAR - Dove Medical Press - August 4th, 2021
- Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma - Curetoday.com - June 7th, 2021
- Autophagy suppresses the formation of hepatocyte-derived cancer-initiating ductular progenitor cells in the liver - Science Advances - June 7th, 2021
- Cancer research: New advances and innovations - Medical News Today - June 7th, 2021
- Fulvestrant Alone Found to be Superior to Venetoclax/Fulvestrant Combo in ER+/HER2- Breast Cancer - Targeted Oncology - June 7th, 2021
- Merck's KEYTRUDA Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal... - June 7th, 2021
- Stem cell study illuminates the cause of an inherited heart disorder | Penn Today - Penn Today - February 14th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with... - February 14th, 2021
- The Very First Signs of an Immune Response Have Been Filmed in a Developing Embryo - ScienceAlert - February 14th, 2021
- Arlo's Army needs stem cell donor as mum begs for help to save three-year-old's life - Glasgow Live - February 14th, 2021
- Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV (enfortumab vedotin-ejfv) in Patients with Previously... - February 14th, 2021
- [Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT - Dove Medical Press - February 14th, 2021
- The drug treatments offering the best hope of a way out of the Covid crisis - Telegraph.co.uk - February 14th, 2021
- In the war against Covid, an arsenal of drugs is on the way - Telegraph.co.uk - February 14th, 2021
- Kat Wests husband, Jeff West, sentenced to 16 years in wifes death - AL.com - February 9th, 2021
- Harnessing the Potential of Cell and Gene Therapy - OncLive - February 9th, 2021
- I Survived Cancer, and Then I Needed to Remember How to Live - The Atlantic - February 9th, 2021
- [Full text] Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor f | CMAR - Dove Medical Press - February 9th, 2021
- West Belfast woman to be remembered in special TV documentary - Belfast Live - January 29th, 2021
- UTV documentary tells of young Belfast woman's lasting legacy to promote stem cell donation - The Irish News - January 29th, 2021
- L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL - Targeted Oncology - January 29th, 2021
- Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes... - January 29th, 2021
- If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News - January 29th, 2021
- Experimental taphonomy of organelles and the fossil record of early eukaryote evolution - Science Advances - January 29th, 2021